Long Term Efficacy and Safety

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Hansa Biopharma
Hansa BiopharmaSweden - Lund
1 program
1
Imlifidase administered in the 20-HMedIdeS-19Phase 31 trial
Active Trials
NCT05937750RecruitingEst. Apr 2030

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
Hansa BiopharmaImlifidase administered in the 20-HMedIdeS-19

Clinical Trials (1)

NCT05937750Hansa BiopharmaImlifidase administered in the 20-HMedIdeS-19

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group

Start: Jul 2023Est. completion: Apr 2030
Phase 3Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space